Disk diffusion and MIC quality control ranges for BC-3205 and BC-3781, two novel pleuromutilin antibiotics

Journal of Clinical Microbiology

Volumn 50, Issue 10, 2012, Pages 3361-3364

  Ross, James E ^a   Sader, Helio S ^a   Ivezic Schoenfeld, Zrinka ^b   Paukner, Susanne ^b   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b Nabriva Therapeutics Inc   (Austria)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BC 3205; BC 3781; LEVOFLOXACIN; PLEUROMUTILIN; RETAPAMULIN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BROTH DILUTION; CONTROLLED STUDY; DISK DIFFUSION; HAEMOPHILUS INFLUENZAE; LABORATORY DIAGNOSIS; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; STANDARDIZATION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; DITERPENES; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; QUALITY CONTROL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

HAEMOPHILUS INFLUENZAE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 84866466514     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01294-12     Document Type: Article

References (10)

1. Clinical and Laboratory Standards Institute. 1 February 2012, accession date. CLSI Subcommittee on Antimicrobial Susceptibility Testing meeting minutes, 2010. CLSI, Wayne, PA. http://www.clsi.org/Content/Navigation Menu/Committees/Microbiology/AST/ArchiveofPreviousEvents/Summary -Minutes-Jan-2010.pdf.
2. Clinical and Laboratory Standards Institute. 2009. M02-A10. Performance standards for antimicrobial disk susceptibility tests; approved standard: 10th ed. CLSI, Wayne, PA.
3. Clinical and Laboratory Standards Institute. 2009. M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: 8th ed. CLSI, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2008. M23-A3. Development of in vitro susceptibility testing criteria and quality control parameters: 3rd edition. CLSI, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2012. M100-S22. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement. CLSI, Wayne, PA.
6. Novak R, Shlaes DM. 2010. The pleuromutilin antibiotics: a new class for human use. Curr. Opin. Investig. Drugs 11:182-191.
7. Ross JE, Jones RN. 2005. Quality control guidelines for susceptibility testing of retapamulin (SB-275833) by reference and standardized methods. J. Clin. Microbiol. 43:6212- 6213.
8. Sader HS, Biedenbach DJ, Paukner S, Ivezic-Schoenfeld Z, Jones RN. 2012. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. Antimicrob. Agents Chemother. 56:1619 -1623.
9. Sader HS, et al. 2012. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for communityacquired respiratory tract infections (CARTIs). J. Antimicrob. Chemother. 67:1170 -1175.
10. Turnidge J, Bordash G. 2007. Statistical methods for establishing quality control ranges for antibacterial agents in Clinical and Laboratory Standards Institute susceptibility testing. Antimicrob. Agents Chemother. 51: 2483-2488. (Pubitemid 47047327)